Economic Burden of Psoriasis Treatment
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
Economic Burden of Psoriasis Treatment
Reading File
Searching PubMed
psoriasis economic burden treatment costs
Searching the Web
economic burden psoriasis treatment costs 2024 2025 biologic therapies
Finding Sources
Reading Article
PMID: 42420624
Reading Article
PMID: 40930460
Finding Sources
Searching PubMed
psoriasis treatment cost-effectiveness biologics phototherapy
Finding Sources
Reading Article
PMID: 41739454
Finding Sources
Reading File
Reading File
Here is a thorough synthesis of the economic burden of psoriasis treatment, integrating the latest peer-reviewed evidence, clinical textbook data, and pharmacoeconomic analyses:
Economic Burden of Psoriasis Treatment
1. Global Scale
The global economic burden of psoriasis reached $148.85 billion in 2021, comprising:
- $95.15 billion in direct healthcare costs
- $53.70 billion in indirect costs (productivity losses)
These figures come from a 2026 systematic analysis covering global disease burden from 1990-2021 (Wei et al., J Invest Dermatol 2026, PMID 40930460), which also found that the number of people living with psoriasis nearly doubled between 1990 and 2021 to 43 million cases, with a Bayesian model forecasting continued upward trends through 2040. High-income countries bear the majority of healthcare costs, while lower-income countries suffer disproportionate productivity losses.
In the United States alone, the total economic burden has been estimated to exceed $110 billion annually, with most attributable to moderate-to-severe disease affecting roughly 20% of the ~8 million Americans with psoriasis.
2. Direct Medical Costs
A. Biologic Agents (Dominant Cost Driver)
Biologics produce the most dramatic clinical responses but at enormous cost. Annual US costs by drug class:
| Drug / Class | Annual Payer Cost (US) |
|---|---|
| Biologics (average, all classes) | ~$84,000/year |
| Bimekizumab (IL-17A/F inhibitor) | ~$84,034/year |
| Ustekinumab (IL-12/23) | ~$87,243/year |
| Brodalumab (IL-17R) | ~$48,782/year |
| Adalimumab (TNF-alpha) | Lower with biosimilars |
Key findings from Kong & Buzney (JAMA Dermatology 2026, PMID 41739454):
- Mean annual total payer costs: biologics $84,034 vs. office phototherapy $14,760 vs. home phototherapy $6,222
- Net willingness to pay for payers was negative for biologics (-$59,926) but positive for home phototherapy (+$11,694) - meaning biologics cost more than the QALY gains justify at the $100,000/QALY threshold
- Patients, however, preferred biologics most (personal WTP +$22,107), creating a payer-patient incentive misalignment
B. Cost per Response Achieved
From comparative meta-analyses of IL-class biologics:
- Cost per PASI 75 responder is similar across newer biologics
- Monthly cost per PASI 90/100 responder is lowest for IL-17 inhibitors (secukinumab, ixekizumab) and highest for older agents (etanercept: ~$40,000/month per PASI 90 responder)
- IL-17 inhibitors are considered the most cost-effective biologics for moderate-to-severe plaque psoriasis
C. Conventional Systemic and Topical Agents
These represent far more affordable options:
- Methotrexate: Remains the benchmark comparator; very low cost (~$10-30/month for the drug itself)
- Cyclosporine: Available ~$23/month for 30 days, but not suitable for long-term use
- Topical corticosteroids: First-line for limited disease; minimal cost
- Phototherapy (NB-UVB): Highly cost-effective - $14,760/year for office-based and only $6,222/year for home-based treatment; considered the most cost-efficient modality for widespread psoriasis (Andrews' Diseases of the Skin)
D. Step-Therapy Strategies
A step-therapy approach (phototherapy first, switch to biologics at 16 weeks if PASI90 not achieved) achieves similar PASI reductions (95.2%) to biologics alone (91.6%), with less variability and substantially lower system costs, and represents an important cost-containment strategy.
3. Indirect and Societal Costs
Indirect costs are a major component of total burden and include:
- Work absenteeism and presenteeism: Studies show psoriasis patients lose significant workdays. Moderate-to-severe disease is particularly disabling.
- Productivity losses contributed $53.7 billion of the 2021 global burden - representing 36% of total costs
- Psychiatric comorbidities: Psoriasis has high rates of depression and anxiety, which compound functional impairment and healthcare use
- Cardiovascular and metabolic comorbidities: Patients with psoriasis and a comorbidity (e.g., CVD) incur roughly double the hospital use and costs compared to non-comorbid patients
- Psoriasis + psoriatic arthritis: ~$9,900 in additional annual costs
- Psoriasis + CVD: Significantly elevated additional cost burden
Per a Springer 2026 review on economic impact of timely systemic treatment, early treatment of psoriasis to prevent comorbidities (CVD, diabetes, mental health disorders) may yield meaningful long-term cost savings.
4. Comorbidity-Related Cost Amplification
Comorbidities - particularly metabolic syndrome, psoriatic arthritis, depression, and cardiovascular disease - are most prevalent in moderate-to-severe psoriasis. Treatment selection must be tailored, as shown in the comorbidity-therapy matrix from Dermatology 2-Volume Set 5e:
- Psoriatic arthritis: MTX, anti-TNF, anti-IL-17, anti-IL-12/23, JAK inhibitors all appropriate
- Crohn's disease: Avoid IL-17 agents
- Congestive heart failure: Avoid anti-TNF (higher grades)
- Depression: Most agents compatible; apremilast with some caution
- These restrictions frequently push patients toward more expensive options, raising costs
5. Payer vs. Patient Cost Perspectives
| Perspective | Preferred Option | Reason |
|---|---|---|
| Payer | Home phototherapy, then adalimumab among biologics | Lower system costs, acceptable QALY gains |
| Patient | Biologics (especially bimekizumab) | Largest quality-of-life gains, lower out-of-pocket burden |
| Out-of-pocket costs | Biologics: $2,000/year (with insurance); Office NB-UVB: $5,004/year | Insurance typically covers biologics heavily |
This divergence in incentives highlights the need for policy interventions such as improved coverage for home phototherapy, which offers the best cost-value proposition at the system level.
6. UK and International Perspectives
A 2026 systematic review of UK NHS cost-utility analyses (Clemmet et al., Pharmacoeconomics 2026, PMID 42420624) found that while modelling methods for psoriasis are well-established (induction and maintenance phase structures), future analyses should better incorporate treatment sequencing, real-world effectiveness data, and comorbidity impacts, as current models may underestimate total costs.
For generalized pustular psoriasis (GPP), a rarer but more severe form, mean annual direct costs are approximately $23,675 per patient per year (2024 USD), ranging from $7,791 (Sweden) to $49,891 (Canada).
7. Biosimilars and Cost Mitigation
The entry of biosimilar adalimumab has created meaningful cost savings for payers. Budget impact analyses show formulary inclusion of biosimilar adalimumab in the US produces significant cost reductions. Biosimilars are increasingly central to formulary management strategies aimed at lowering psoriasis treatment expenditure.
Summary
| Cost Category | Estimate |
|---|---|
| Global total economic burden (2021) | $148.85 billion |
| Direct healthcare costs (global) | $95.15 billion |
| Indirect/productivity costs (global) | $53.70 billion |
| US annual burden (moderate-severe) | >$110 billion |
| Annual biologic cost (US payer) | ~$48,000-$87,000/patient |
| Annual phototherapy (home NB-UVB) | ~$6,222/patient |
| Comorbidity cost multiplier | ~2x hospitalizations |
Biologics, particularly IL-17 inhibitors, are the most clinically effective but most expensive treatment modality. Phototherapy - especially home-based NB-UVB - offers the best cost-effectiveness from a payer standpoint. Step-therapy and biosimilar adoption represent the most practical system-level cost-containment strategies. The burden is expected to continue growing through 2040 as psoriasis prevalence rises globally.
Key references:
- Wei et al., J Invest Dermatol 2026 (PMID 40930460) - Global burden 1990-2021
- Kong & Buzney, JAMA Dermatol 2026 (PMID 41739454) - Biologics vs. phototherapy cost modeling
- Clemmet et al., Pharmacoeconomics 2026 (PMID 42420624) - UK cost-utility systematic review
- Andrews' Diseases of the Skin, 13e; Dermatology 2-Volume Set 5e; Fitzpatrick's Dermatology
This is a shared conversation. Sign in to Orris to start your own chat.